ArticleCancer discovery2020

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.

Patrizia Mondello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.